Hammerstone Pro Trader

This Powerful Solution Allows You To Communicate & Collaborate In Real-Time Alongside Our Pro Data Stream

 

Get A Competitive Edge In Your Trading With The Hammerstone’s Unique Real-Time Data & Analysis

Our Partners

What Is Hammerstone Pro Trader?

All our monthly plans come with a 14-day free trial and no fixed contract.

Hammerstone Pro Feed

The Hammerstone Pro Feed is our most powerful solution and a trusted resource that has been providing Wall Street with data since 2001. Using either Bloomberg’s IB manager, Symphony and other platforms, the Pro feed allows you to communicate and collaborate with other Pro traders in real-time to discuss intra-day news, markets and securities. The chat window allows you to see the news and chat stream simultaneously.

START A 14 DAY FREE TRIAL

Hammerstone Reports

Hammerstone Reports are expertly written daily updates sent 4 times per day directly to your inbox. These reports give you an in-depth analysis of earnings reports, street recommendations, economic data, sector news, market movers and more. Here are examples of the reports:

START A 14 DAY FREE TRIAL

Get Started With Hammerstone Pro For Free

Hammerstone Reports

4x Daily Reports

$49/mo

Start Your Free 14 Day Trial

  • Up-To-Date Reports (4x Daily)
  • News & In-Depth Analysis
  • Early Look Edition
  • Mid Morning Look Edition
  • Street Recommendations Edition
  • Daily Recap Edition
  • Delivery via Email
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

Hammerstone Pro Trader

Get the Pro feed only

$299/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

  • Strictly For The Professional Trader
  • Pro Trader Data Feed
  • Real Time Chat Alongside Data Feed
  • Pro Members Vetted To Maintain Chat Room Integrity
  • Filter functionality in data feed
  • Real-Time Breaking News With Context
  • Proprietary Research
  • Delivery via Web/Bloomberg/Symphony
  • Desktop & Mobile Compatible
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

COMPLETE PRO TRADER PACKAGE

Pro Trader Data Feed + 4X Daily Reports

$329/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

  • All Features of Pro Data Feed & Reports
  • Real Time Chat Alongside Data Feed
  • Pro Members Vetted To Maintain Chat Room Integrity
  • Real-Time Breaking News With Context
  • Actionable Ideas, Running Commentary
  • Earnings Releases & Interpretation
  • Proprietary Research & Index Levels
  • Delivery via Web App (No Install Required)
  • 4x Daily Editions Of Hammerstone Reports
  • Desktop & Mobile Compatible
  • 14-Day Free Trial
  • Cancel Anytime

Start Your Free 14 Day Trial

No obligations, no contracts, cancel at any time, 100% risk free.

Here’s Yesterday’s Market Pro Sample Feed

Please Note: This Is A Delayed Example (without the Chat Room), Not The Live Feed.

  • Posted At:2019-04-21T21:30:07Z

    U.S. EQUITY PREVIEW: ANTM, AKRX, BA, CI, CVS, FRAN, INTC, ISRG By Tatiana Darie (Bloomberg) -- U.S. stocks that may move Monday following news over the weekend: Francesca’s Holdings (FRAN): rose late Friday after reporting 4Q preliminary sales and delayed its 10-K filing. Akorn (AKRX): The drugmaker rose late Friday after gaining FDA approval for its nasal spray. Intuitive Surgical (ISRG): Shares fell post-market Friday as higher spending projections overshadowed its procedure growth guidance. Funko (FNKO): Filed up to 32 million shares for selling holders. Lyft (LYFT): For Lyft, whose stock has tumbled sharply since its March 28 launch, it took less than three weeks for disillusioned shareholders to sue the company over claims they were taken for a ride. Spotify (SPOT): At current prices, the stock’s potential reward isn’t worth the risk, Barron’s said in its latest cover story. UnitedHealth Group (UNH), Anthem (ANTM), Cigna (CI), Humana (HUM) and CVS Health (CVS) look appealing, Barron’s said, adding that "Medicare-for-All" looks like a long shot. Watch health insurers as former Vice President Joe Biden is making preparations to enter the Democratic presidential campaign with a possible announcement as soon as next Wednesday, according to people familiar with his plans. Boston Beer (SAM): Investors shouldn’t rush to buy the stock as big stock swings around earnings and a hoppy valuation give reason for pause, Barron’s sai.d Intel (INTC) could be the big winner after Apple (AAPL) and Qualcomm (QCOM) reached a six-year patent-licensing deal and agreed for Qualcomm to supply chipsets to Apple, Barron’s said. Boeing’s (BA) factory in North Charleston, S.C., has faced problems with production and oversight that create a safety threat, NY Times reported, citing a review of internal emails, corporate documents and federal records, as well as interviews with more than a dozen current and former employees.

  • Posted At:2019-04-20T16:01:13Z

    *BOEING DREAMLINER PLANT `PLAGUED BY SHODDY PRODUCTION': NYT $BA

  • Posted At:2019-04-18T20:32:10Z

    Aphria Secures Cannabis Cultivation License in Germany PR Newswire LEAMINGTON, ON, April 18, 2019 LEAMINGTON, ON, April 18, 2019 /PRNewswire/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that its German subsidiary Aphria Deutschland GmbH ("Aphria Germany") has secured the previously announced license for the domestic cultivation of medical cannabis from the German Federal Institute for Drugs and Medical Devices ("BfArM"), following the conclusion of a mandatory 10-day standstill period for public contracts. Aphria was granted a cultivation license for four of the nine total lots awarded by BfArM and is awaiting the completion of the tender process for the four remaining lots under review, one of which was provisionally awarded to Aphria Germany.

  • Posted At:2019-04-18T20:30:14Z

    *BANCFIRST 1Q EPS 96C, EST. 93C

  • Posted At:2019-04-18T20:27:18Z

    ISSUER: Zosano Pharma Corp SYMBOL: ZSAN FILER: Walker John Peter TITLE: Chairman of the Board DATE TRANSACTION SHARES PRICE VALUE 4/11/19 Purchase 100,000 $3.50 $350,000 OWNERSHIP: 280,228 (Direct)

  • Posted At:2019-04-18T20:20:25Z

    *U.S. HIGH-YIELD FUNDS SEE INFLOWS OF $1.1B IN WEEK: LIPPER

  • Posted At:2019-04-18T20:15:22Z

    SRCE US1st Source reported earnings per share for the first quarter of 86c. 1Q net interest margin 3.78% 1Q return on average assets 1.43% 1Q return on average equity 11.6%

  • Posted At:2019-04-18T20:11:13Z

    INDB reported operating earnings per share for the first quarter that matched the average analyst estimate. 1Q operating EPS $1.30, estimate $1.30 (range $1.26 to $1.34) (Bloomberg data) 1Q EPS $1.25 1Q tangible book value per share $29.64 .

  • Posted At:2019-04-18T20:10:16Z

    *INDB 1Q OPER EPS $1.30, EST. $1.30

  • Posted At:2019-04-18T20:08:34Z

    DUBLIN, Ireland, April 18, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in newly diagnosed, treatment naïve patients with AL Amyloidosis and cardiac dysfunction (N=260), which was discontinued in 2018. The final hazard ratio (HR) for the composite primary endpoint (time to all-cause mortality or time to cardiac hospitalization more than 90 days after first infusion of study drug) of 0.835 (95% CI: 0.5799, 1.2011; p=0.3300) was consistent with the futility analysis reported in April 2018. Post hoc analyses of all-cause mortality revealed a potential survival benefit favoring NEOD001 in the category of patients at highest risk for early mortality (Mayo Stage IV, n=77) with a HR of 0.544 (95% CI: 0.2738, 1.0826; p=0.0787). This potential survival benefit was more pronounced in Mayo Stage IV patients during the initial 12 months of treatment, with a HR of 0.498 (95% CI: 0.2404, 1.0304; p=0.0556).

  • Posted At:2019-04-18T20:06:37Z

    *UNITED INSURANCE SEES 1Q NET CATASTROPHE LOSSES $18M PRETAX UIHC,UNIN JR

  • Posted At:2019-04-18T20:05:55Z

    *INTUITIVE SURGICAL 1Q REV. $974M, EST. $973.4M

  • Posted At:2019-04-18T20:04:52Z

    *FRANCESCA'S SEES PRELIMINARY 4Q ADJ LOSS 1C-3C PER SHARE

  • Posted At:2019-04-18T20:03:05Z

    18 Apr - 04:02:49 PM [RTRS] (.SPX .IXIC) - FOR THE WEEK, THE S&P FELL 0.08%, THE DOW ADDED 0.56%, THE NASDAQ GAINED 0.17%

  • Posted At:2019-04-18T20:01:43Z

    ANDOVER, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com) today announced the acquisitions of The Athena Group, Inc. (Athena) and Syntonic Microwave LLC (Syntonic). The all cash purchase price for both transactions was $46 million in total. Both transactions are subject to net working capital and net debt adjustments. The acquisitions were funded through Mercury’s existing revolving credit facility, and are not expected to have a material impact on Mercury’s financial results for the fourth quarter or full fiscal year 2019.

Get Started With Hammerstone Pro For Free

Hammerstone Reports

4X Daily Reports

$49/mo

Start Your Free 14 Day Trial

Hammerstone Pro Trader

Get the Pro feed only

$299/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

COMPLETE PRO TRADER PACKAGE

Pro Trader Data Feed + 4x Daily Reports

$329/mo
* Discounts Available For Multiple Licenses

Start Your Free 14 Day Trial

No obligations, no contracts, cancel at any time, 100% risk free.

Witness The Hammerstone In Action

CASE STUDY: $IRTC
(Irhythm Technologies, Inc.)

case study

$IRTC (Irhythm Technologies, Inc.)– During an Apple, Inc. ($APPL) presentation, we noted early that $APPL was entering the digital health market, where $IRTC is the dominant player. Soon after, the stock preceded to move lower as more traders recognized the same theme we identified (Apple moving into the this sector was negative for them).


CASE STUDY: $SFLY
(Shutterfly, Inc.)

case study

$SFLY (Shutterfly, Inc.)– Hammerstone was quick with analysis after Amazon had released a new product which would be direct a competitor to Shutterfly. After listing the Amazon price points on the product, we noted technical levels as $SFLY proceeded to drop 10%.


CASE STUDY: $SYF
(Synchrony Financial)

case study

$SYF (Synchrony Financial)– This chart highlights our ability to pull up past broker comments/research related to breaking news.

As Walmart, Inc ($WMT) headlines crossed the tape about possibly ending its partnership with $SYF, Hammerstone was able to add context and quantify our news flow by describing exactly how valuable that loss could be to $SYF.

This allowed our clients to make educated trading decisions within seconds of the breaking news as the street realized how detrimental this might be to $SYF.


CASE STUDY: $MAXR
(Maxar Technologies, Ltd.)

case study

$MAXR (Maxar Technologies, Ltd.) – The Hammerstone Market Feed does an excellent job aggregating data/flow from many different sources.

Here, we immediately disseminated a short report on $MAXR as it was released while highlighting the important data points in the report.

By being relaying this information quickly, our clients were able to take early advantage in $MAXR before the price deterioration in the stock.


CASE STUDY: $VERI
(Veritone, Inc.)

case study

$VERI (Veritone, Inc.)– $VERI is an example of how Hammerstone adds idea generation with our curation.

$VERI stock rose from below $10 to above $70 in short period of time. Hammerstone quickly realized a potential disconnect in valuation between $ACTG(Acacia Research, Corp)/$VERI and, more importantly, the fact $ACTG owned 4 million shares of $VERI.

We noted a likelihood of $ACTG liquidating their position after the rapid price appreciation of $VERI. Hammerstone early in our analysis and well ahead of other services and news outlets (noted on chart) as stock dropped 35% intraday.